Transdermal HRT: patches, gels and the oral comparison

What is transdermal HRT?

Transdermal HRT delivers hormones through the skin. For menopausal treatment, the estrogen component commonly comes as an estradiol patch, gel or spray. These are systemic treatments: the aim is to deliver estrogen into the circulation to treat symptoms such as hot flashes and night sweats. A product applied to the skin is therefore different from a low-dose vaginal estrogen used mainly for local discomfort. Transdermal does not mean weak, cosmetic or free of systemic risks. [1], [2], [9]

Oral and transdermal estrogen can both be useful. The choice depends on the treatment goal, medical history, uterine protection, tolerability, practical routine and access. NICE asks clinicians to discuss the route alongside hormone type, dose, schedule and duration. A patch cannot settle the whole decision on its own, especially when someone has a history of thrombosis, cancer, unexplained bleeding or cardiovascular disease. [1]

How do oral estrogen, patches and gels compare?

This is a comparison of routes, not a ranking of products or an instruction to switch. The VTE wording above reports NICE's guidance; it cannot establish that an individual has no clot risk. The product labels themselves retain contraindications, including previous or current thromboembolism. A clinician needs to reconcile guidance with the named medicine and your history. [1], [3], [4]

Why might a clinician suggest the skin route?

Estrogen taken through skin avoids the initial passage through the liver that occurs after absorption of an oral medicine. The Estradot label describes this difference, including the possibility that enzyme-inducing medicines affect transdermal hormones less than oral hormones. It does not say that transdermal products have no interactions. Tell the prescriber about all medicines and supplements instead of assuming the route solves them. [3]

NICE recommends considering transdermal rather than oral HRT when VTE risk is increased, including a BMI over 30. Someone at high VTE risk, such as a person with a strong family history or hereditary thrombophilia, may need hematology assessment before HRT is considered. That is a reason for a more careful conversation, not permission to begin a patch despite a contraindication in the label. [1]

Preferences also matter. You might prefer a patch because there is no daily gel application, or prefer gel because adhesive irritates your skin. Travel, swimming, work hours, caring for children, dexterity and supply can affect how consistently a product fits your life. These practical details are worth explaining. They are not evidence that one route delivers the same amount to every person or that a convenient product is suitable for every medical history. [2], [3], [4]

Does a patch remove breast cancer, stroke or clot risk?

No single route removes every relevant risk. NICE distinguishes oral from transdermal estrogen in its VTE and stroke advice. Its discussion of stroke notes that important route comparisons come from observational evidence. Such studies can inform decisions, but treatment users may differ in ways that random assignment would balance. Do not turn a population comparison into a personal guarantee. [1], [12]

Breast cancer discussion also requires the estrogen-only versus combined distinction, treatment duration and baseline history. NICE says evidence is insufficient to establish whether breast cancer risk differs between combined preparations containing micronised progesterone or dydrogesterone and preparations containing other progestogens. Changing the estrogen route does not settle that uncertainty. Similarly, a transdermal estrogen prescription does not eliminate the need for endometrial protection when it is required. [1], [5]

The purpose of treatment matters. NICE does not recommend combined or estrogen-only HRT for primary or secondary prevention of cardiovascular disease, or for dementia prevention. Symptom treatment, fracture prevention in a suitable product-specific context and cardiovascular prevention are different questions. Do not interpret a possible vascular advantage over oral estrogen as proof that patches prevent heart attacks or dementia. [1]

New chest pain, sudden breathlessness, one-sided leg swelling or stroke symptoms require urgent medical assessment. Persistent local irritation can usually be discussed with the prescribing team, but severe allergy, marked skin injury or concerning systemic symptoms warrant earlier help. Mention the actual medicine and when symptoms began. A diary or an assumption about estrogen absorption should not delay care. [3], [4]

What do patch and gel numbers actually mean?

The number printed on a patch usually describes a release rate, not the total amount inside it. One checked UK example is Estradot 50: the patch contains 0.78 mg estradiol and releases 50 mcg per 24 hours. Its label specifies replacement twice weekly, every three to four days. The reservoir content, release rate and replacement interval answer different questions. Multiplying the release rate by a week does not produce a new application instruction. [3]

Gel packaging uses another set of units. The checked UK Oestrogel label says one pump dispenses 1.25 g of gel containing 0.75 mg estradiol. The grams describe the gel; the milligrams describe its active ingredient. This is not a claim that all that estradiol enters the bloodstream. A different pump, sachet or spray may contain and deliver a different amount. [4]

These are label-reading examples, not suggested starting doses or a patch-to-gel conversion. Read the product name, concentration, number of prescribed applications and instructions together. If a pharmacy supplies an alternative, ask for the new written plan and leaflet before treating the old routine as interchangeable. A record should say both the medicine and the relevant unit, not simply “estrogen 50” or “one pump.” [2], [3], [4]

Can I convert a patch into pumps or cut it?

Conversion tables help clinicians plan alternatives, but they are approximate. BMS's practical-prescribing tool, amended August 2026, says its estimates combine pharmacokinetics, trials and clinical experience. Absorption and metabolism vary enough that dose equivalence cannot be precise. Its usual-menopause-age table excludes premature ovarian insufficiency. It also distinguishes doses outside product licensing and notes uncertainty about additional benefit and risk at higher doses. [2]

A switch needs more than an equivalent-looking number. Confirm when to remove or finish the old medicine, when to start the new one, whether estrogen exposure is changing, whether progestogen needs review, and when to reassess symptoms and bleeding. Shortages do not make combining leftover products or increasing applications a safe default. Ask the pharmacist or prescriber for a plan that matches the actual supply. [2], [5]

Do not assume a patch can be cut because another person's patch was cut. The design and label matter, and cutting is not a general application instruction in the checked Estradot label. Likewise, a fraction of a pump is not automatically a reliable measured amount. This guide does not provide an improvised taper, substitution or higher-dose regimen. Product-specific decisions belong with the prescribing team. [2], [3], [4]

What application details should I confirm?

Use the leaflet for the exact product. Estradot's UK instructions specify clean, dry abdominal skin, avoiding the breasts, waistline and damaged or irritated skin. They require site rotation and at least one week before returning to the same site. They also give specific instructions for a patch that falls off or is missed. Those details should not be copied indiscriminately to a differently labeled patch. [3]

Oestrogel's checked UK label specifies suitable clean, dry, intact skin and excludes the breasts and vulval region. It says to allow five minutes to dry before clothing, wash hands after application, avoid skin contact for one hour, and avoid washing or other skin products on the area for at least one hour. It warns about transfer to other people, particularly children, and describes covering the area if needed. Other gels and sprays may have different application areas and contact intervals. [4]

An application problem is useful information for a pharmacist: a patch repeatedly lifting, a rash under the adhesive, difficulty handling the backing, a gel that remains inconveniently tacky, or concern about close contact with a child. Describe it before adding creams, adhesives, occlusive dressings or a different site. A workaround from a public discussion may change tolerability or use and may not match the label. [3], [4]

It can help to rehearse the routine while looking at the box and leaflet: where it goes, when it is changed or applied, what to do if forgotten, and how to avoid exposing other people. Ask for instructions in a format you can use. A simple schedule is valuable only when it records the prescribed routine accurately; reminder software cannot resolve a dosing ambiguity.

Does transdermal estrogen still need progesterone?

If you have a uterus, systemic estrogen generally needs adequate endometrial protection. The estrogen reaching your body through skin still stimulates the endometrium. Protection may come from an appropriate separate progestogen, a suitable combined product or another specifically assessed option. The required amount and pattern depend on estrogen exposure, product, bleeding context and clinical history. [1], [5]

Sequential and continuous plans differ. Continuous estrogen does not automatically mean continuous progestogen, and a patch change day is not a progestogen cycle. A combined patch may already contain a progestogen; an estrogen-only patch does not. Confirm the names and roles of every item rather than adding or removing progesterone based on the word “patch.” [2], [3], [5]

After a total hysterectomy, estrogen-only treatment is often appropriate, but endometriosis and other history can change the discussion. Contraception is another separate question: menopausal HRT is not contraceptive treatment. Do not assume that any contraceptive pill or hormonal IUD automatically supplies the necessary HRT protection for its entire contraceptive lifespan. Product, duration and jurisdiction matter. [1], [5], [8]

What follow-up is useful after starting or changing route?

NICE recommends review at three months and annually thereafter, with earlier review when treatment is ineffective, poorly tolerated or raises safety concerns. The review should ask whether the problem you wanted treated has improved, whether the routine is workable, and whether adverse effects or bleeding require assessment. A route change should come with a clear plan for reassessment, not an expectation to chase a blood number indefinitely. [1]

Hormone blood tests are not a universal scorecard. The current WHC patient factsheet and BMS estradiol tool explain important variation and limitations. A clinician may sometimes request a level for a defined question, but there is no single blood concentration that proves ideal symptom control, correct absorption or absence of risk for every person. A result needs the medicine, timing, clinical purpose and relevant laboratory context. [7], [13]

Bleeding follows its own safety pathway. NICE describes common bleeding within the first six months after starting systemic HRT or within three months after a dose or preparation change, with prompt medical help beyond those periods. Heavy, prolonged or higher-risk bleeding may need earlier assessment under BMS guidance. These windows do not instruct you to ignore concerning bleeding. Changing route does not make new bleeding automatically harmless. [1], [6]

What do public accounts add?

Two checked discussions show why route preference is personal. Selected accounts describe useful symptom relief with patches or gels, convenience with less frequent patch changes, difficulty remembering daily application, adhesive irritation and inconvenient drying. Some people describe better control after switching; others describe poorer control or a new practical problem. These are selected experiences, not comparative trials or a response rate. [10], [11]

The same conversations contain improvised dose changes, uncertain explanations of absorption and suggested skin treatments. Those suggestions were not adopted as clinical advice here. The useful next step is to turn a practical concern into a question: “My patch lifts before its change day,” or “The gel routine is hard to complete safely.” A clinician can then check the named product and plan rather than treating another person's experience as your prescription.

What should I record for a follow-up visit?

Record the product name, labeled strength, prescribed amount and schedule, and the date of any agreed change. For a patch, distinguish its release-rate unit from how many patches you use and when they are replaced. For gel, record the actual formulation and prescribed applications. Keep the progestogen plan separately visible when it is a separate medicine.

Choose a small number of symptoms that matter to you, such as night sweats interrupting sleep or hot flashes affecting work. Brief notes about function can be more useful than a large score sheet. Add meaningful missed applications, persistent skin problems and bleeding dates without concluding that every variation proves poor absorption. Bring the package or a clear photo if the product has changed.

A symptom record supports a conversation; it cannot diagnose a clot, establish endometrial protection or choose a dose. Doserly tracks the schedule you and your clinician choose. It does not recommend doses. If you cannot tell which unit belongs in a reminder, clarify the prescription first.

What questions are worth asking?

Are patches always better than tablets?

No. NICE describes route differences particularly relevant to VTE and stroke, but the whole decision includes indication, personal history, uterine protection and preferences. A favorable comparison with oral treatment does not erase a product’s contraindications or guarantee absence of risk for an individual. Ask why the suggested route fits your situation and how practical problems would be handled. The route-choice section explains the clinical context; choosing a patch should remain a product-specific decision rather than a universal ranking of all tablets and skin treatments. [1], [3], [4]

Do gel and patch estrogen stay only where I apply them?

No. Menopausal transdermal estrogen passes through the skin and provides systemic treatment. Applying a medicine to a limited area does not mean its effects remain there. Low-dose local vaginal estrogen has a different treatment purpose and exposure, while some vaginal products are themselves systemic. Confirm the exact formulation when comparing options. The comparison section separates delivery route from treatment purpose, so that application location does not lead you to omit required uterine protection or expect local treatment to control hot flashes. [1], [2]

Does 50 mcg mean the patch contains 50 mcg?

Not necessarily. In the checked UK Estradot 50 example, 50 mcg per 24 hours describes the release rate, while the patch contains 0.78 mg estradiol. Its replacement instruction is twice weekly, every three to four days; content, rate and interval are separate quantities. These are label-reading examples, not a starting dose or a conversion to another patch. The units section explains what to confirm if a pharmacy supplies a different formulation or the number on the pack is unclear. [3]

Is one pump the same across gels?

No. The checked UK Oestrogel pump dispenses 1.25 g gel containing 0.75 mg estradiol per actuation. Another pump, sachet or spray can have a different concentration and amount, and the dispensed estradiol is not a universal absorbed dose. Do not carry an old pump count into a new product without the new instructions. The units section distinguishes gel mass, active ingredient and absorption; ask the pharmacist or prescriber to clarify the actual pack and prescribed application before changing your routine. [4]

Can I switch route without reviewing progesterone?

Confirm the whole plan with the prescribing team. If estrogen exposure changes and you need endometrial protection, the protection must be reconciled with the new regimen, including its actual preparation and schedule. Do not stop the protective component because estrogen is now applied through the skin. Bring both medicine names and ask when to finish the old treatment, begin the new one and review symptoms or bleeding. The uterine-protection section explains why a route change is not only an estrogen conversion. [2], [5]

Should I increase estrogen when a blood result seems low?

Not on the number alone. Estradiol measurements have limitations and should answer a defined clinical question rather than provide a universal optimization target. Timing, formulation and application can affect interpretation, and persistent symptoms can have another cause. Discuss the actual product, instructions, symptom pattern and reason for the test before a clinician considers adjustment. The follow-up section explains how clinical response and safety are assessed together; a low-looking result does not justify extra applications, mixing products or omitting protection. [7], [13]

What if my patch irritates my skin?

Ask the pharmacist or prescriber to assess the exact product, site and reaction. Reviewing application or discussing another preparation may help, but the guide does not prescribe creams, tape, cutting or a new dose as a workaround. Follow the product’s site-rotation and skin instructions, and seek earlier help for a marked reaction or concerning systemic symptoms. The application section distinguishes product-specific instructions from general advice; a photo and dates can help explain the problem without assuming every adhesive reaction has the same cause. [3], [4]

Does switching to gel reset the bleeding clock?

A preparation change is relevant to NICE’s bleeding context, but it does not justify dismissing heavy, prolonged or otherwise concerning bleeding. Describe the old and new products, change date, bleeding pattern and actual progestogen use when seeking advice. Clinical risk factors and the BMS pathway can call for earlier assessment regardless of a settling-in period. The follow-up section explains the distinction between routine review and a bleeding concern; repeated changes should not become a way to postpone investigation of a persistent problem. [1], [6]

Glossary

Terms used in assessment and care.

Perimenopause

The transition toward menopause, with changing ovarian hormone patterns and possible symptoms.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excessive growth of the uterine lining; distinct from a cancer diagnosis.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Local vaginal estrogen

A low-dose product intended mainly for genitourinary symptoms.

Vasomotor symptoms

Hot flashes and night sweats.

Genitourinary syndrome of menopause

A group of menopause-associated vaginal, sexual and urinary symptoms.

Hysterectomy

Surgical removal of the uterus; the extent of surgery matters.

Oophorectomy

Surgical removal of one or both ovaries.

Sequential combined HRT

Estrogen through the cycle with progestogen on specified days.

Continuous combined HRT

Estrogen and progestogen supplied continuously.

Withdrawal bleeding

Bleeding that can follow completion of a scheduled progestogen course.

Unscheduled bleeding

Bleeding outside the expected pattern of the agreed treatment.

Contraception

A method intended to prevent pregnancy; menopausal HRT is not one.

IUD

Intrauterine device; type and indication determine its role.

Bioidentical

Chemically identical to a hormone made by the body; not a guarantee of safety.

Compounded preparation

A specially prepared medicine, not automatically equivalent to an approved product.

Observational study

A study observing people without randomly assigning the treatment being examined.

Release rate

The amount a product releases over a stated time; not total reservoir content.

Reservoir content

The total medicine held in a patch or ring, not its daily delivery rate.

Formulation

The specific concentration and delivery preparation of a medicine.

First-pass effect

The initial liver passage after absorption of an oral medicine; avoided with transdermal delivery.

Adhesion

How a patch stays attached to the skin.

Secondary transfer

Unintended exposure of another person through contact with an application site.

Thrombophilia

A condition associated with a greater tendency to form blood clots.

Venous thromboembolism

A blood clot in a vein, including deep-vein thrombosis or pulmonary embolism.

Approximate equivalence

A clinician planning estimate that does not guarantee identical exposure or effect.

How was this guide researched?

Source selection and limits

Current NICE recommendations and rationale anchor route-related decisions. The complete BMS August 2026 practical tool supplies equivalence limitations; its dose table is not reproduced. Current original UK Estradot and Oestrogel SmPCs provide explicitly labeled unit and application examples, not general regimens. BMS endometrial/bleeding guidance, current hormone-testing information and FSRH contraception guidance retain their scope. Two directly accessible public discussions provide selected practical themes; no unsupported self-adjustment, mechanistic explanation or skin workaround was adopted. Route-related vascular evidence includes observational comparisons, and a favorable comparison does not erase product contraindications.

This is an AI-assisted Doserly editorial guide checked October 2, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical record-keeping suggestions are editorial advice, not a validated diagnostic scale or clinical-monitoring system. Material new guidance, labels or safety information trigger earlier source review.

Sources